Showing results (671-680 of 794) with videos related to

Sort By:
Pageof 80
The Lancet. Oncology|January 1, 2016
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate dataClaire L Vale, Sarah Burdett, Larysa H M Rydzewska, et al.
BJU International|April 8, 2015
Risk of prostate cancer mortality in men with a history of prior cancerKathryn T Dinh, Brandon A Mahal, David R Ziehr, et al.
Bioorganic & Medicinal Chemistry Letters|May 25, 2005
Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13Mark C Noe, Vijayalakshmi Natarajan, Sheri L Snow, et al.
Bioorganic & Medicinal Chemistry Letters|September 3, 2003
Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-alpha converting enzyme inhibitorsMichael A Letavic, John T Barberia, Thomas J Carty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2017
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without DocetaxelLauren C Harshman, Yu-Hui Chen, Glenn Liu, et al.
The Journal of Urology|July 27, 2011
Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancerPeter Chang, Konrad M Szymanski, Rodney L Dunn, et al.
The New England Journal of Medicine|August 6, 2015
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerChristopher J Sweeney, Yu-Hui Chen, Michael Carducci, et al.
The American Journal of Medicine|February 4, 2015
Who bears the greatest burden of aggressive treatment of indolent prostate cancer?Brandon A Mahal, Matthew R Cooperberg, Ayal A Aizer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2024
Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate CancerChristopher J Sweeney, Russell Petry, Chang Xu, et al.
Parasites & Vectors|July 18, 2026
Comparative speed of kill of induced Ixodes scapularis infestations following treatment of dogs with endectocides containing either sarolaner (Simparica Trio™), afoxolaner (NexGard® PLUS), or lotilaner (Credelio Quattro™)Kathryn E Reif, Todd M Kollasch, Casey L Locklear, et al.
Pageof 80